BridgeBio Oncology Therapeutics News and Activities

BridgeBio Oncology Therapeutics is owned by BridgeBio.

BridgeBio is one of the...

• Russell 3000;
• TOB Iconic 10,000.

BridgeBio is a company listed under the stock ticker BBIO (US).

Acquisition, funding and merger involving BridgeBio.

• BridgeBio has just announced a $1,000 Million fundraising (posted on July 2 2026).

View the org chart displaying its 23 main executives

Most searched biographies at BridgeBio Oncology Therapeutics

• Pedro Beltran, Chief Executive Officer
• Jake Bauer, Non-Executive Director
• Peter Lebowitz, Director

Popular executive movements at BridgeBio Oncology Therapeutics

• Michelle Doig, Director, has left the company  (posted on June 23 2026).
• Eli Wallace, Chief Executive Officer, has left the company  (posted on April 23 2026).
• Neil Kumar, who was Director, is promoted to Executive Chairman of the Board  (posted on April 23 2026).

Click here to view some more movements at BridgeBio Oncology Therapeutics

Popular executive movements at BridgeBio

• Danny Scott has joined the company as Director of Training and Development  (posted on June 29 2026).
• Maggie Sweeney has joined the company as Senior Director, Clinical Quality and Compliance  (posted on May 6 2026).
• Julie Miller Everett, who was Chief Business Officer, is promoted to Chief Operating Officer, Skeletal Dysplasias  (posted on April 23 2026).

Click here to view some more movements at BridgeBio

Create your alert
to follow the executive moves at BridgeBio Oncology Therapeutics.

BridgeBio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by BridgeBio Oncology Therapeutics

Social media about BridgeBio Oncology Therapeutics

• BridgeBio Oncology Therapeutics on Wikipedia, Google News & Yahoo Finance
• BridgeBio Oncology Therapeutics on LinkedIn, X (Twitter) & YouTube